PC
CRSP icon

Paulson & Co’s CRISPR Therapeutics CRSP Stock Holding History

Paulson & Co’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-28,500
Closed -$457K – 60
2017
Q2 		$457K Sell
28,500
-22,000
-44% -$363K 0.01% 105
2017
Q1 		$1.1M Buy
+50,500
New +$991K 0.01% 92

Other funds holding CRSP

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GTP
Global Thematic Partners New York $120M AUM 25.18% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Paulson & Co's CRSP Position: Q3 2017 in Review

Paulson & Co sold out of CRISPR Therapeutics (CRSP) in Q3 2017, closing a stake of 28,500 shares — an estimated $457K sold.

Paulson & Co first reported a position in CRSP in Q1 2017 and held it in 2 quarters. The position peaked at $1.1M in Q1 2017. 64 funds tracked by Wall St. Rank hold CRSP as of Q3 2017.

  • Paulson & Co reported no remaining CRISPR Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Paulson & Co sold 28,500 CRISPR Therapeutics shares in Q3 2017, an estimated $457K.
  • Paulson & Co first reported a position in CRISPR Therapeutics in Q1 2017 and held it in 2 quarters.
  • Paulson & Co's CRISPR Therapeutics position peaked at $1.1M in Q1 2017.
  • 64 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2017.

Based on Paulson & Co's 13F filing for Q3 2017, filed 14 Nov 2017.